Xtant Medical (NYSEAMERICAN:XTNT) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) posted its quarterly earnings data on Tuesday. The medical device company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02), Zacks reports. Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%. The firm had revenue of $27.94 million for the quarter. Xtant Medical updated its FY 2024 guidance to EPS.

Xtant Medical Stock Down 4.3 %

Shares of XTNT traded down $0.02 during trading hours on Friday, reaching $0.43. 130,039 shares of the company traded hands, compared to its average volume of 102,024. The firm has a market capitalization of $59.69 million, a P/E ratio of -3.30 and a beta of 0.39. Xtant Medical has a 1-year low of $0.43 and a 1-year high of $1.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.01 and a current ratio of 2.12.

Analyst Upgrades and Downgrades

Separately, Craig Hallum set a $1.50 price target on shares of Xtant Medical and gave the company a "buy" rating in a report on Friday, October 18th.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.